Physician profile
Ezzat Nashed
NPI 1336106640
$2,313.91
in general payments reported to CMS, 2019-2025
20 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $398 · 2021: $419 · 2022: $290 · 2023: $208 · 2024: $224 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.84 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $860.14 | 2019-2025 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $498.20 | 2021-2025 | |
| Pfizer INC. | $392.90 | 2019-2024 | |
| Amgen INC. | $92.69 | 2020-2023 | Otezla, Repatha |
| Lilly USA, LLC | $89.15 | 2019-2025 | Mounjaro |
| Glaxosmithkline, LLC. | $46.65 | 2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $45.72 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $36.65 | 2021 | |
| Janssen Pharmaceuticals, INC | $27.52 | 2019 | |
| Edwards Lifesciences Corporation | $26.70 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Dexcom, INC. | $26.45 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $23.74 | 2024 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $22.29 | 2019 | |
| Electromed, INC. | $21.89 | 2024 | Smartvest |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.54 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.58 | 2022 | |
| Exact Sciences Corporation | $17.90 | 2024 | Cologuard Collection Kit |
| Biogen, INC. | $16.11 | 2020 | |
| Merck Sharp & Dohme LLC | $14.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ezzat Nashed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.